BACKGROUND: Acute decompensation of maple syrup urine disease (MSUD) is usually treated by enteral feeding with an amino-acid mixture without leucine (Leu), valine or isoleucine. However, its administration is ineffective in cases of gastric intolerance and some adult patients refuse enteral feeding via a nasogastric tube. We developed a new parenteral amino-acid mixture for patients with MSUD. METHODS: Seventeen decompensation episodes in four adult patients with MSUD treated with a parenteral amino-acid mixture (group P) were compared to 18 previous episodes in the same patients treated by enteral feeding (group E). RESULTS: The mean Leu concentration at presentation was similar in the groups P and E (1196.9 μmol/L and 1212.2 μmol/L, respectively). The mean decrease in the Leu concentration during the first 3 days of hospitalisation was significantly higher in group P than group E (p = 0.0026); there were no side effects. The mean duration of hospitalisation was similar (4 vs. 4.5 days, p = NS). No patient in group P deteriorated whereas one patient in group E required dialysis. CONCLUSION: This new parenteral amino-acid mixture is safe and allows efficient Leu concentration decrease during acute MSUD decompensation episodes in adults. Its use avoids the need for nasogastric tube insertion.
BACKGROUND: Acute decompensation of maple syrup urine disease (MSUD) is usually treated by enteral feeding with an amino-acid mixture without leucine (Leu), valine or isoleucine. However, its administration is ineffective in cases of gastric intolerance and some adult patients refuse enteral feeding via a nasogastric tube. We developed a new parenteral amino-acid mixture for patients with MSUD. METHODS: Seventeen decompensation episodes in four adult patients with MSUD treated with a parenteral amino-acid mixture (group P) were compared to 18 previous episodes in the same patients treated by enteral feeding (group E). RESULTS: The mean Leu concentration at presentation was similar in the groups P and E (1196.9 μmol/L and 1212.2 μmol/L, respectively). The mean decrease in the Leu concentration during the first 3 days of hospitalisation was significantly higher in group P than group E (p = 0.0026); there were no side effects. The mean duration of hospitalisation was similar (4 vs. 4.5 days, p = NS). No patient in group P deteriorated whereas one patient in group E required dialysis. CONCLUSION: This new parenteral amino-acid mixture is safe and allows efficient Leu concentration decrease during acute MSUD decompensation episodes in adults. Its use avoids the need for nasogastric tube insertion.
Authors: G T Berry; R Heidenreich; P Kaplan; F Levine; A Mazur; M J Palmieri; M Yudkoff; S Segal Journal: N Engl J Med Date: 1991-01-17 Impact factor: 91.245
Authors: Philippe Jouvet; Philippe Hubert; Jean Marie Saudubray; Daniel Rabier; Nguyen K Man Journal: Pediatr Res Date: 2005-07-07 Impact factor: 3.756
Authors: Kevin A Strauss; Bridget Wardley; Donna Robinson; Christine Hendrickson; Nicholas L Rider; Erik G Puffenberger; Diana Shellmer; Diana Shelmer; Ann B Moser; D Holmes Morton Journal: Mol Genet Metab Date: 2010-01-12 Impact factor: 4.797
Authors: Patrick R Blackburn; Jennifer M Gass; Filippo Pinto E Vairo; Kristen M Farnham; Herjot K Atwal; Sarah Macklin; Eric W Klee; Paldeep S Atwal Journal: Appl Clin Genet Date: 2017-09-06
Authors: Paula Sánchez-Pintos; Silvia Meavilla; María Goretti López-Ramos; Ángeles García-Cazorla; Maria L Couce Journal: Front Pediatr Date: 2022-08-15 Impact factor: 3.569